Stevan Shaw
Overview
Explore the profile of Stevan Shaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen S, Blijdorp I, van Mens L, Bowcutt R, Latuhihin T, van de Sande M, et al.
J Rheumatol
. 2020 Jan;
47(11):1606-1613.
PMID: 31941804
Objective: Targeting the interleukin 17 (IL-17) axis is efficacious in psoriasis and spondyloarthritis (SpA), but not in rheumatoid arthritis (RA). We investigated potential differences in tissue expression and function of...
12.
Glatt S, Taylor P, McInnes I, Schett G, Landewe R, Baeten D, et al.
Ann Rheum Dis
. 2019 Jun;
78(8):1033-1040.
PMID: 31177099
Objective: Evaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid...
13.
Smith B, Kiessling A, Lledo-Garcia R, Dixon K, Christodoulou L, Catley M, et al.
MAbs
. 2018 Aug;
10(7):1111-1130.
PMID: 30130439
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), has been developed to reduce pathogenic IgG in autoimmune and alloimmune diseases. We document the antibody isolation...
14.
Lightwood D, Tservistas M, Zehentleitner M, Sarkar K, Turner A, Bracher M, et al.
Am J Respir Crit Care Med
. 2018 Jun;
198(5):610-619.
PMID: 29883204
Rationale: IL-13 is an important cytokine implicated in the pathogenesis of allergic asthma and is an attractive target for an inhaled therapeutic. Objective: To investigate the efficacy of CDP7766, a...
15.
Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson A, et al.
Ann Rheum Dis
. 2017 Dec;
77(4):523-532.
PMID: 29275332
Objective: Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear....
16.
Glatt S, Helmer E, Haier B, Strimenopoulou F, Price G, Vajjah P, et al.
Br J Clin Pharmacol
. 2016 Nov;
83(5):991-1001.
PMID: 27859546
Aims: To assess safety, pharmacokinetics (PK) and clinical efficacy of bimekizumab (formerly UCB4940), a novel humanized monoclonal antibody and dual inhibitor of interleukin (IL)-17A and IL-17F, in subjects with mild...
17.
Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(5):388-95.
PMID: 27129012
Interleukin-6 (IL-6) is implicated in the pathophysiology of several inflammatory conditions. Olokizumab, a humanized anti-IL-6 monoclonal antibody, selectively blocks the final assembly of the IL-6 signaling complex. A randomized, double-blind,...
18.
Shock A, Burkly L, Wakefield I, Peters C, Garber E, Ferrant J, et al.
Arthritis Res Ther
. 2015 Sep;
17:234.
PMID: 26335795
Introduction: CD40 ligand (CD40L) blockade has demonstrated efficacy in experimental autoimmune models. However, clinical trials of hu5c8, an anti-human CD40L IgG1 antibody, in systemic lupus erythematosus (SLE) were halted due...
19.
Moore A, Allden S, Bourne T, Denis M, Kranidioti K, Okoye R, et al.
J Transl Med
. 2014 Oct;
12:285.
PMID: 25344414
Background: Novel molecules that specifically target human TNFα in rheumatoid arthritis pose problems for preclinical assessment of efficacy. In this study collagen antibody-induced arthritis (CAIA) has been induced in human...
20.
Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, et al.
MAbs
. 2014 Mar;
6(3):774-82.
PMID: 24670876
Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody...